Kết quả điều trị ban đầu u lympho Hodgkin trẻ em tại Viện Huyết học - Truyền máu Trung ương giai đoạn 2017 - 2023=Results of initial treatment of pediatric Hodgkin lymphoma at National Institute of Hematology and Blood Transfusion in 2017

Kết quả điều trị ban đầu u lympho Hodgkin trẻ em tại Viện Huyết học - Truyền máu Trung ương giai đoạn 2017 - 2023=Results of initial treatment of pediatric Hodgkin lymphoma at National Institute of Hematology and Blood Transfusion in 2017 - 2023

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Thị Hưng Dương, Thu Hằng Dương, Thị Hồng Hoàng, Lan Mai, Thị Ngãi Nguyễn, Thị Ngọc Phạm, Quỳnh Mai Trần, Thanh Tùng Trần

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2024

Mô tả vật lý: tr.143-151

Bộ sưu tập: Metadata

ID: 478226

Thêm vào giỏ

Childhood Hodgkin lymphoma is one of the cancers that responds well to chemotherapy and radiation therapy. Objective: Analyze the results of initial treatment of pediatric Hodgkin lymphoma at the National Institute of Hematology and Blood Transfusion in the period 2017 - 2023. Research subjects and methods: Case series descriptive study: 24 pediatric patients diagnosed with Hodgkin lymphoma, was treated at the Pediatric Department, National Institute of Hematology and Blood Transfusion. Results: The study demonstrated that the response rates to treatment according to the EuroNet - PHL - C1 and BEACOPP regimens were 100% and 50%, respectively. A later stage of diagnosis was associated with a lower response rate to treatment. In stages I - II, the response rate to first-line treatment was 100%, while in stages III - IV it was 75%. The response rates for children in the high-risk and non-highrisk groups were 75% and 91.7%, respectively. The overall survival rate and 3-year progressionfree survival rate in the study cohort were 100% and 70.8%, respectively. The side effects and complications associated with the EuroNet - PHL - C1 regimen were lower than those of the BEACOPP regimen. Univariate analysis of factors affecting treatment outcomes revealed no statistically significant impact of variables such as gender, age, disease stage, LDH levels, β2- microglobulin, or risk group on the probability of progression-free survival. Conclusion: The study recorded a good initial response rate in the group of pediatric Hodgkin lymphoma patients treated at the National Institute of Hematology and Blood Transfusion.U lympho Hodgkin trẻ em là một trong số những bệnh ung thư đáp ứng tốt với hóa chất và xạ trị. Mục tiêu: Phân tích kết quả điều trị ban đầu U lympho Hodgkin trẻ em tại Viện Huyết học - Truyền máu Trung ương giai đoạn 2017 - 2023. Đối tượng và phương pháp nghiên cứu: Nghiên cứu mô tả loạt ca bệnh: 24 bệnh nhi được chẩn đoán xác định là U lympho Hodgkin, điều trị tại khoa Bệnh máu trẻ em, Viện Huyết học - Truyền máu Trung ương. Kết quả: Nghiên cứu cho thấy tỷ lệ đáp ứng với điều trị theo phác đồ EuroNet - PHL - C1 và BEACOPP lần lượt là 100% và 50%. Chẩn đoán bệnh ở giai đoạn càng muộn thì tỷ lệ đáp ứng với điều trị càng thấp. Ở giai đoạn I - II, tỷ lệ đáp ứng với điều trị hàng một là 100%, trong khi đó ở giai đoạn III - IV là 75%. Tỷ lệ đáp ứng điều trị của bệnh nhi thuộc nhóm nguy cơ cao và không cao lần lượt là 75% và 91,7%. Xác suất sống thêm toàn bộ và xác suất sống thêm bệnh không tiến triển 3 năm của nhóm bệnh nhi nghiên cứu lần lượt là 100% và 70,8%. Các tác dụng phụ, biến chứng của phác đồ EuroNet - PHL - C1 thấp hơn so với phác đồ BEACOPP. Khi phân tích đơn biến các yếu tố ảnh hưởng đến kết quả điều trị, chúng tôi nhận thấy chưa có tác động có ý nghĩa thống kê của các yếu tố như giới tính, tuổi, giai đoạn bệnh, LDH, β2-microglobulin và nhóm nguy cơ đ ến xác suất sống thêm bệnh không tiến triển. Kết luận: Nghiên cứu ghi nhận tỷ lệ đáp ứng ban đầu khá tốt trên nhóm bệnh nhi U lympho Hodgkin điều trị tại Viện Huyết học - Truyền máu Trung ương.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR